Faeth Therapeutics (FTH)
NasdaqMarket Closed
Last updated
- Market Cap
- $1,034,909,021
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- $1,008,006,021
- Sector
- Materials
- Industry
- Pharmaceutical Preparations
- Address
- 1405 RESEARCH BLVD, SUITE 125, ROCKVILLE, MD, 20850
Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $1,034,909,021
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- $1,008,006,021
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 5.98
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -5.07
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- -7.57
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -$33,862,000
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -113.05%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -103.29%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 19.69
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 19.69
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 2.81
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- $301,563
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 40.05
Income Statement
| Line Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 |
| Operating income | -18.39M | -170.63M | -4.96M | -4.85M | -5.21M |
| EBITDA | -18.36M | -170.6M | -4.91M | -4.82M | -5.17M |
| Net income | -16.01M | -170.24M | -4.72M | -4.57M | -4.94M |
| Income taxes | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | -3K | -6K | 0 |
| Other operating expenses | 0 | 0 | 0 | 0 | 0 |
| Total operating expenses | 18.39M | 170.63M | 4.96M | 4.85M | 5.21M |
| Basic EPS | -2.84 | -131.45 | -3.74 | -3.62 | -3.91 |
| Diluted EPS | -2.84 | -131.45 | -3.74 | -3.62 | -3.91 |
Balance Sheet
| Line Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Total assets | 189.31M | 205.38M | 22.9M | 27.59M | 31.78M |
| Total liabilities | 9.58M | 14.19M | 4.31M | 4.58M | 4.47M |
| Total equity | 172.96M | -137.29M | 18.59M | 23.01M | 27.31M |
| Cash & equivalents | 26.9M | 152.33M | 8.67M | 10.56M | 12.56M |
| Current assets | 188.66M | 204.23M | 21.51M | 25.79M | 29.57M |
| Current liabilities | 9.58M | 14.19M | 4.25M | 4.44M | 3.87M |
| Accounts payable | 7.57M | 8.98M | 1.48M | 1.41M | 1.14M |
| Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventories | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Long-term debt | 0 | 0 | 0 | 0 | 4K |
Cash Flow
| Line Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Operating cash flow | -15.67M | -10.73M | -3.86M | -3.59M | -5.91M |
| Investing cash flow | -108.07M | -31.44M | 2.08M | 1.74M | 8.76M |
| Financing cash flow | -1.68M | 185.83M | -111K | -152K | -168K |
| Change in cash | -125.42M | 143.66M | -1.89M | -2M | 2.68M |
| Net income | -16.01M | -170.24M | -4.72M | -4.57M | -4.94M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | SCHEDULE 13G/A — Faeth Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Faeth Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Faeth Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Faeth Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Faeth Therapeutics, Inc. | View Filing | |
| edgar index | 10-Q — Faeth Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Faeth Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 3 — Faeth Therapeutics, Inc. | View Filing | |
| form 3 | Form 3 — Khosla Ventures Seed Associates D, LLC | View Filing | |
| form 3 | Form 3 — Khosla Ventures VI, L.P. | View Filing | |
| form 3 | Form 3 — Khosla Ventures Seed Associates D, LLC | View Filing | |
| form 3 | Form 3 — Khosla Ventures VI, L.P. | View Filing | |
| form 3 | Form 3 — Khosla Ventures Associates VI, LLC | View Filing | |
| form 3 | Form 3 — VK Services, LLC | View Filing | |
| form 3 | Form 3 — Khosla Ventures Associates VI, LLC | View Filing | |
| form 3 | Form 3 — VK Services, LLC | View Filing | |
| form 3 | Form 3 — Khosla Ventures Seed D, L.P. | View Filing | |
| form 3 | Form 3 — Khosla Ventures Seed D, L.P. | View Filing | |
| form 3 | Form 3 — KHOSLA VINOD | View Filing | |
| form 3 | Form 3 — KHOSLA VINOD | View Filing | |
| edgar index | 8-K — Faeth Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Faeth Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Faeth Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Craver Josiah | View Filing | |
| form 4 | Form 4 — Parikh Anand Kiran | View Filing | |
| edgar index | 4 — Faeth Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| edgar index | 4 — Faeth Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| edgar index | 4 — Faeth Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Faeth Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| edgar index | SCHEDULE 13G — Faeth Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Faeth Therapeutics, Inc. | View Filing | |
| edgar index | 3 — Faeth Therapeutics, Inc. | View Filing | |
| form 3 | Form 3 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — Parikh Anand Kiran | View Filing | |
| form 4 | Form 4 — Parikh Anand Kiran | View Filing | |
| form 4 | Form 4 — Parikh Anand Kiran | View Filing | |
| form 4 | Form 4 — Parikh Anand Kiran | View Filing | |
| form 4 | Form 4 — Parikh Anand Kiran | View Filing | |
| edgar index | S-3ASR — Faeth Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Faeth Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 3 — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 4/A — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 3 — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Sensei Biotherapeutics, Inc. | View Filing | |
| form 3 | Form 3 — Ramasastry Saira | View Filing | |
| form 3 | Form 3 — Ramasastry Saira | View Filing | |
| form 3 | Form 3 — Hahn Stephen M. | View Filing | |
| edgar index | 8-K — Sensei Biotherapeutics, Inc. | View Filing |